Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter phase Ib-II dose-escalation of trabectedin (Yondelis) in combination with oxaliplatin in patients with cancer pretreated advanced ovarian. [Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis) en association avec l'oxaliplatine chez des patientes atteintes d'un cancer de l'ovaire avancé prétraité.]

Trial Profile

Multicenter phase Ib-II dose-escalation of trabectedin (Yondelis) in combination with oxaliplatin in patients with cancer pretreated advanced ovarian. [Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis) en association avec l'oxaliplatine chez des patientes atteintes d'un cancer de l'ovaire avancé prétraité.]

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jul 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxaliplatin (Primary) ; Trabectedin (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaMar

Most Recent Events

  • 14 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top